Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00462072 · ClinicalTrials.gov registry record · Phase 4
Centocor Microarray Study of Patients
A Phase 4 study of Rheumatoid Arthritis and Psoriasis, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT00462072: Completed Phase 4 study of Rheumatoid Arthritis and Psoriasis, sponsored by University of Rochester.
NCT00462072 is a Phase 4 study of Rheumatoid Arthritis and Psoriasis that has completed, run by University of Rochester. The registered enrollment target is 31 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00462072, a Phase 4 study of Rheumatoid Arthritis and Psoriasis, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
Specific Aim 1. To determine the transcriptome of peripheral blood mononuclear cells isolated monocytes and target tissues in IMIDs. Specific Aim 2. To analyze the change in gene expression profiles in patients with Crohn's disease, psoriatic and rheumatoid arthritis before and after infliximab therapy.
Primary Outcome
The DAS28 for RA and PsA subjects is an outcome measure used in determining the severity of an individual's disease. This score is used to assess disease activity and to make and monitor treatment decisions. The baseline DAS28 is an average of the study populations baseline disease activity score prior to the administration of Infliximab (remicade). A DAS28 score of higher than 5.1 is indicative of high disease activity, whereas a DAS28 below 3.2 indicates low disease activity. A subject is cons
Conditions Studied
Interventions
- DRUG Infliximab
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2007-03 |
| Est. Completion | 2010-08 |
| Phase | Phase 4 |
What the finished NCT00462072 record still lists
NCT00462072 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Infliximab is the first listed.
NCT00462072 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00462072 about?
NCT00462072 is a clinical study titled "Centocor Microarray Study of Patients". Specific Aim 1. To determine the transcriptome of peripheral blood mononuclear cells isolated monocytes and target tissues in IMIDs. Specific Aim 2. To analyze the change in gene expression profiles in patients with Crohn's disease, psoriatic and rheumatoid arthritis before and after infliximab the...
What is the current status of trial NCT00462072?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2007-03. Estimated completion is 2010-08.
What conditions does trial NCT00462072 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Psoriatic Arthritis.
What interventions are being tested in trial NCT00462072?
The interventions under investigation include: Infliximab (DRUG).
Who is sponsoring clinical trial NCT00462072?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00462072 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00462072's enrollment target sits among peer trials
31 159th of 197 higher than 37 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NSAIDs vs. Coxibs in the Presence of Aspirin
RECRUITING · Phase 4
-
Improving Bone Health Among Rheumatoid Arthritis (RA) Patients on Chronic Glucocorticoids
COMPLETED · Phase 4
-
A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis
COMPLETED · Phase 4
-
Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis
COMPLETED · Phase 4
-
A Study of Baricitinib in Participants With Rheumatoid Arthritis
COMPLETED · Phase 4
-
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia